Analyst consensus rating
Keros Therapeutics Analyst Rating: Buy
Direct answer
Keros Therapeutics's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $19.83.
Forecast evidence checked September 4, 2026.
Get free Keros Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.35
- Average price target
- $19.83
- High price target
- $25.00
- Low price target
- $16.00
- Low target gap
- +41%
- Target upside
- +74.7%
- High target gap
- +120.3%
- Target range width
- 79.3%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Keros Therapeutics?
Keros Therapeutics has a verified Buy consensus. The same dataset has an average price target of $19.83.
How far are Keros Therapeutics's low and high targets from the recorded price?
The low target implies +41%, while the high target implies +120.3%.
How many analysts are included in Keros Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Keros Therapeutics's target upside or downside calculated?
The average target of $19.83 is divided by the recorded price of $11.35, then one is subtracted to produce +74.7%. This does not guarantee a future return.
When was Keros Therapeutics's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.